BVF Inc 13F Portfolio

CIK 1056807 Filing since Q1 2014 Q3 2026 filed Nov 16, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 16, 2026.

Portfolio Snapshot

42 positions · Q3 2026

BVF Inc reported 42 positions worth $2.97B for the quarter ended Sep 30, 2026, down 16.9% on the prior quarter. It opened 2 new positions, added to 6, trimmed 15 and exited 0. Its largest holding is Revolution Medicines, Inc. at 17% of the portfolio.

Portfolio Value
$2.97B
-16.9% QoQ · +34.6% YoY
Positions
42
2 new · 0 sold out
Top 10 Concentration
67.5%
of portfolio value
Largest Position
RVMD 17%
Revolution Medicines, Inc.
Net Buying
-$158.82M
$178.83M bought · $337.65M sold
Turnover
5.5%
of the portfolio traded
Top Sector
Healthcare
100% of value
Track Record
51
quarters on file since Q1 2014

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

1 sectors
100%
Healthcare
Healthcare100%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareOtherIndustrials

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
TYRA Tyra Biosciences, Inc. +2.74M +185.6% $59.92M 3.1%
ALKS Alkermes plc. +692.4K +32.1% $28.06M 3.88%
STOK Stoke Therapeutics, Inc. +1.06M +41.7% $27.60M 3.16%
PYXS Pyxis Oncology, Inc. +11.83M – $27.55M 0.927%
ALEC Alector, Inc. +10.05M – $18.59M 0.625%
SGMT Sagimet Biosciences Inc. +1.00M +40.0% $9.88M 1.16%
CBIO Crescent Biopharma, Inc. +344.8K +12.5% $5.03M 1.52%
OKUR OnKure Therapeutics, Inc. +809.5K +25.0% $2.21M 0.371%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
RVMD Revolution Medicines, Inc. -504.6K -17.0% $103.57M 16.99%
IRON Disc Medicine, Inc. -920.3K -79.8% $60.24M 0.514%
MIRM Mirum Pharmaceuticals, Inc. -648.8K -61.4% $55.46M 1.17%
XNCR Xencor Inc -906.7K -12.7% $22.62M 5.23%
GPCR Structure Therapeutics Inc. -675.4K -20.1% $21.12M 2.83%
KURA Kura Oncology, Inc. -1.76M -20.8% $18.80M 2.41%
AVTX Avalo Therapeutics, Inc. -1.17M -56.3% $17.91M 0.468%
NKTR Nektar Therapeutics -257.1K -10.8% $15.56M 4.35%
PVLA Palvella Therapeutics, Inc. -65.6K -9.8% $9.05M 2.82%
ZYME Zymeworks Inc. -185.0K -5.1% $4.90M 3.09%

New Positions

Q3 2026
Holding Shares Trade Value Weight
PYXS Pyxis Oncology, Inc. +11.83M $27.55M 0.927%
ALEC Alector, Inc. +10.05M $18.59M 0.625%

Closed Positions

Q3 2026

No positions were closed this quarter.

Holdings · Q3 2026

42 Positions

As ofSep 30, 2026
Value$2.97B
Top 1067.5%
Avg position$70.78M
# Activity
27 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 42 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Bvf.

About BVF Inc’s 13F Portfolio

What are BVF Inc’s largest holdings?

As of its Q3 2026 13F filing, BVF Inc’s five largest positions were Revolution Medicines, Inc. (RVMD) at 17.0%, Kymera Therapeutics, Inc. (KYMR) at 14.6%, GH Research PLC (GHRS) at 6.8%, MoonLake Immunotherapeutics (MLTX) at 6.3%, Xencor Inc (XNCR) at 5.2% of the reported portfolio.

How much is BVF Inc’s portfolio worth?

BVF Inc reported a 13F portfolio worth $2.97B across 42 positions for Q3 2026. That is down 16.9% from the previous quarter.

What did BVF Inc buy in Q3 2026?

Its largest purchases by value were Tyra Biosciences, Inc. ($59.92M), Alkermes plc. ($28.06M), Stoke Therapeutics, Inc. ($27.60M). It opened 2 new positions.

What did BVF Inc sell in Q3 2026?

Its largest sales by value were Revolution Medicines, Inc. ($103.57M), Disc Medicine, Inc. ($60.24M), Mirum Pharmaceuticals, Inc. ($55.46M). It exited 0 positions entirely.

Where does this data come from?

From the Form 13F-HR reports BVF Inc files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.